What Corvalol Treats: Main Uses and Benefits

Corvalol is generally applied across domains where additional symptomatic support is needed for conditions characterized by functional nervous tension. It is commonly used to help with emotional stress, nervousness, and states of increased irritability that interfere with daily stability. The preparation includes components intended to support symptom management in areas requiring calming assistance. This supportive relief contributes to easing distress associated with these symptoms, including restlessness and stress-related insomnia in mild functional nervous states.

The preparation is relevant for managing symptoms related to heightened physiological activity or physical discomfort, which include functional tachycardia (palpitations), minor non-acute spasms of coronary vessels, and gastrointestinal cramping. It may be part of symptomatic management in conditions like Vegetative Vascular Dystonia (VVD). This generally supports general well-being during symptomatic phases and assists with maintaining functional stability when symptoms become more noticeable.

“This medication is primarily relevant when supportive symptom management is appropriate for easing functional physical and emotional tension.”

Quick Fact: Relief for Functional Discomfort
Primary Focus: Symptomatic relief in contexts of increased tension and physical discomfort.
Common Use: Applied during phases when symptoms of emotional tension and related physical discomfort become more noticeable.

Regulatory References

1. National Institutes of Health (NIH) resource

Eligibility Map: Who Can and Cannot Use Corvalol

Official regulatory documents define strict population eligibility for Corvalol, primarily based on the restrictions of its Phenobarbital component.

Classification	Regulatory Status
Populations for Whom Use is Contraindicated	Hypersensitivity to barbiturates; Acute intermittent porphyria; Severe respiratory depression or pulmonary insufficiency; Severe hepatic or renal impairment; History of drug dependence or abuse.
Age-Related Eligibility	Pediatric: Use is not recommended, and it is contraindicated in hyperkinetic children. Older Adults (Geriatric): Use requires caution and a reduced dose to prevent oversedation and paradoxical effects (e.g., excitement).
Pregnancy and Lactation Status	Pregnancy: Use is generally Avoided (Category D), as documented due to the reported risk of fetal harm. Lactation: Use requires Caution as the drug is present in breast milk, necessitating infant monitoring.
Conditional Use Restrictions	Patients with mild to moderate hepatic or renal impairment require caution and a reduced dosage. Individuals with suicidal tendencies must be administered the medicine with caution, if at all.

The official eligibility profile is defined by these absolute non-eligibility rules and conditional restrictions, limiting use primarily to adult patients who do not possess the specified contraindicating conditions or organ dysfunction.

Corvalol Interactions with other medicines and products

This section outlines interactions officially documented in government regulatory sources, based primarily on the active component Phenobarbital.

---

Documented Pharmacokinetic and Pharmacodynamic Patterns

The most significant pattern is hepatic enzyme induction, where Corvalol's component accelerates the metabolism of co-administered medicines, reducing their plasma concentration and potential effectiveness. This is officially noted for substances like Oral Anticoagulants, Corticosteroids, and Steroidal Hormones (including oral contraceptives), often requiring increased monitoring and adjustment of the co-administered drug. Conversely, substances like Sodium Valproate are documented to increase the barbiturate component's serum levels.

Another key pattern is Additive Central Nervous System (CNS) Depression, officially noted with concomitant use of Alcohol and other CNS-depressant medicines (e.g., other sedatives, hypnotics, and tranquilizers).

Interaction-Related Restrictions

Classification	Interacting Substance/Category	Restriction Rationale
Contraindicated Combination	Monoamine Oxidase Inhibitors (MAOIs)	Prohibited due to inhibited metabolism, leading to prolonged effects of the barbiturate component.
Recommended Avoidance	Griseofulvin	Interference with its absorption is noted, making simultaneous administration generally inadvisable.
High-Risk Interaction	Steroidal Hormones/Oral Contraceptives	Enzyme induction may reduce their effect, suggesting an alternate contraceptive method may be needed.

Corvalol's primary mechanism of action is mediated by its component, ethyl alpha-bromoisovalerate, which acts as a positive allosteric modulator on the GABA A receptor complex in the central nervous system (CNS).

Mechanistic Action

• Biological Targets and Interaction: Ethyl alpha-bromoisovalerate allosterically binds to a distinct site on the GABA A receptor, a ligand-gated chloride ion channel. This binding event enhances the affinity of the inhibitory neurotransmitter, gamma-aminobutyric acid (GABA), for its own binding site.
• Molecular and Intracellular Pathways: The enhanced GABA binding frequency or duration increases the flux of chloride ions ( Cl^-) into the postsynaptic neuron. This influx causes hyperpolarization of the neuronal membrane, which diminishes the cell's excitability and reduces the probability of generating an action potential.
• Downstream Cascades and Physiological Consequences: The generalized suppression of neuronal excitation across the CNS, particularly in brainstem and limbic structures, leads to a system-level reduction in central neuronal activity. This modulation results in CNS depression and a decrease in both peripheral and central reflex excitability. Additionally, the drug's components contribute to direct peripheral vasodilation by relaxing vascular smooth muscle, thereby reducing peripheral resistance and modulating systemic blood pressure.

Official Administration Guidelines

Corvalol is a combination preparation available as an oral liquid solution (drops) and tablets, intended for the oral route of administration.

---

Standard Dosing and Preparation

The standard adult dosing for the liquid solution is typically 15 to 30 drops per single administration. This dose is taken up to 3 times a day. If necessary, the single dose may be increased to a maximum of 40 to 50 drops.

Administration Condition	Instruction
Timing	Should be taken before a meal.
Preparation (Drops)	Dissolve the drops in a small amount of water or place them onto a sugar slice before swallowing.

Treatment Duration

The overall dosage and duration of treatment are established individually. This indicates that the length of the treatment course is not fixed but is determined based on the clinical needs of the patient, within the general framework of use as a sedative and spasmolytic agent.

Corvalol: Recent Clinical Evidence

Clinical data on Corvalol, a combination product containing Phenobarbital and Ethyl ester of alpha-bromoisovaleric acid, are primarily derived from studies focused on its sedative and spasmolytic properties, rather than large-scale, modern randomized controlled trials (RCTs) typically required for regulatory approval in many Western countries.

Key Findings on Efficacy

Research has explored the potential biological actions of the two main components. Studies also examined the preparation's potential for anti-inflammatory effects and sedative action. The active ingredients are associated with effects on the central nervous system (CNS), which may facilitate the onset of natural sleep.

Some observational studies and older clinical data suggest that Corvalol may be associated with improved symptoms in conditions such as:

• Neuroses with heightened irritability.
• Insomnia and sleep disturbances.
• Mild spasms of coronary vessels and tachycardia.

However, a lack of extensive, independent, placebo-controlled RCTs means that definitive conclusions regarding its efficacy for cardiovascular conditions or long-term management of sleep disorders are limited by current evidence standards.

Safety and Tolerability Profile

The most significant component, Phenobarbital, is a barbiturate with known risks for dependence, tolerance, and overdose. Due to its Phenobarbital content, Corvalol is considered a controlled substance in some regions. Spontaneous reports of adverse events primarily include reactions from the central nervous system, such as lethargy, drowsiness, weakness, and dizziness, which are consistent with the known effects of barbiturates.

Studies examining the drug’s safety profile note potential for drug-drug interactions, as phenobarbital is known to induce certain liver enzymes (cytochrome P450), which can alter the effectiveness of other medications.

Key Studies & References

1. Ethyl Bromisovalerianate (Bromisoval): Drug Profile and Clinical Use in Eastern European Countries

Common questions about Corvalol (FAQ)

Q: What is Corvalol used for?

A: Corvalol is a combination product that has historically been used in Eastern European and some Asian countries as a sedative and antispasmodic. Its primary ingredients are ethyl alpha-bromoisovalerate, phenobarbital, and peppermint oil. It is often used to address symptoms of neurosis, mild sleep disturbances, and sometimes as a calming agent for heart-related discomfort not caused by a serious underlying condition. However, it is not approved for medical use by major regulatory bodies like the FDA in the United States or the EMA in Europe due to concerns about the safety and efficacy of its ingredients, particularly phenobarbital.

Q: What are the main ingredients in Corvalol?

A: The primary active ingredients are ethyl alpha-bromoisovalerate, phenobarbital, and peppermint oil. Phenobarbital is a barbiturate, a class of drugs that acts as a central nervous system depressant. Ethyl alpha-bromoisovalerate is a mild sedative. The inclusion of phenobarbital is the main reason for regulatory concerns, as barbiturates carry risks of dependence, overdose, and significant adverse interactions.

Q: Is Corvalol safe to use?

A: Corvalol contains phenobarbital, a barbiturate. Barbiturates are associated with a risk of dependence and can be addictive if used regularly over time. There is also a risk of overdose, especially when combined with other central nervous system depressants, such as alcohol or certain prescription medications. Due to these safety concerns and the lack of comprehensive clinical data, regulatory agencies in many Western countries have not approved this product for medical use. Consult a healthcare provider immediately if you have taken Corvalol and experience dizziness, extreme drowsiness, confusion, or difficulty breathing.

Q: Where is Corvalol legally available?

A: Corvalol is primarily available over-the-counter or by prescription in countries like Russia, Ukraine, and other states in Eastern Europe and Central Asia. It is not legally authorized for sale or importation as a medicine in the United States, Canada, the European Union, or Australia. Importing or possessing it in these regions may be illegal due to the presence of phenobarbital.

How to Store and Dispose of Corvalol?

The storage and stability requirements for Corvalol, as documented in regulatory labeling, are designed to ensure product quality and public safety.

Official Storage Conditions

Requirement	Constraint
Maximum Temperature	Store at a temperature not exceeding 25^circC
Environmental Protection	Must be stored in a place protected from light
Shelf-life	The product's official stability period is 1 year 6 months

Mandatory Safety & Disposal

Official labeling requires that the product be kept out of reach of children to prevent accidental ingestion. No specific instructions regarding the disposal of unused or expired product (e.g., return to pharmacy or do not flush) are explicitly documented in all reviewed regulatory sources, indicating that standard local pharmaceutical disposal procedures should be followed.